Patent ID: 7135197

Claim:
An orally deliverable liquid pharmaceutical suspension comprising: (a) at least one pharmaceutically acceptable bismuth-containing compound present in a total amount of about 0.1 % to about 10%, by weight; (b) an effective suspending amount of at least one pharmaceutically acceptable non-clay-derived suspending agent selected from the group consisting of cellulosic suspending agents, polymeric suspending agents, xanthan gum, silicon dioxide, and mixtures thereof; (c) at least one pharmaceutically acceptable anti-microbial preservative, wherein the preservative does not contain benzoic acid or salts thereof; and (d) water; wherein during storage in a closed container maintained under ambient conditions for a period of at least about 5 months, the suspension exhibits reduced upward pH drift by comparison with an otherwise similar comparative suspension that contains at least 0.1%, by weight, of magnesium aluminum silicate.